knowledge -WSS

knowledge

author：hotspot 2025-09-03 05:29:56 - browse：1716

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： 2023 STAT Wunderkinds: get to know the winners

WSS

Hospital price transparency does save money, advocate argues

Why don't Americans have at

AMAs digital advisors table RPM coding reform proposal, again

Eli Lilly expects to double planned employment in Boston center

Researchers explore possible ties between long Covid, menopause

Solve the antibiotic resistance crisis with preventive drugs

leisure time

knowledge

explore

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Heart attack and stroke risk calculators need revising

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Hepatitis C has a cure — but many Americans still lack access to it

HHS leader on health, climate change and biopharma emissions

Dobbs anniversary: the lost opportunity of abortion as health care

Too many hospitalized Covid

United colonoscopy coverage change 'may cost lives,' doctors say

Latigo launches with $135 million for Vertex

focus

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Why don't Americans have at

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Juul documents reveal insider tactics on political lobbying

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Studies point to risks of excluding people with obesity from drug trials

leisure time

focus

explore

focus